Skip to content
Menu

Citigroup Maintains Buy on Sana Biotechnology, Lowers Price Target to $11

Benzinga Newsdesk 3 days ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Citigroup analyst Samantha Semenkow maintains Sana Biotechnology (NASDAQ:SANA) with a Buy and lowers the price target from $12 to $11.

Citigroup analyst Samantha Semenkow maintains Sana Biotechnology (NASDAQ:SANA) with a Buy and lowers the price target from $12 to $11.

Read at benzinga.com